# Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

> **NCT06407232** · PHASE3 · RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 90 (estimated)

## Conditions studied

- Cytomegalovirus Infections
- Kidney Transplant Infection
- Pancreas Transplant

## Interventions

- **DRUG:** Letermovir

## Key facts

- **NCT ID:** NCT06407232
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-08
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06407232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06407232, "Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06407232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*